Radius Health, Inc. (RDUS)
Jul 10, 2025 - RDUS was delisted (reason: acquired by Toyota Tsusho America)
29.99
-0.01 (-0.03%)
Inactive · Last trade price on Jul 11, 2025

Company Description

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology.

Its commercial product includes TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis.

It also develops abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for the treatment of hyperphagia related to Prader-Willi syndrome.

Radius Health, Inc. has a partnership with EffRx Pharmaceuticals. Radius Health, Inc. was formerly known as MPM Acquisition Corp. and changed its name to Radius Health, Inc. in May 2011.

The company was incorporated in 2003 and is based in Boston, Massachusetts.

Radius Health, Inc.
Radius Recycling logo
Country United States
Founded 2003
IPO Date Nov 15, 1993
Industry Steel
Sector Materials
Employees 3,011
CEO Scott Briggs

Contact Details

Address:
22 Boston Wharf Road
Boston, Delaware 02210
United States
Phone 617-551-4000
Website radiuspharm.com

Stock Details

Ticker Symbol RDUS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000912603
CUSIP Number 806882106
ISIN Number US8068821060
Employer ID 93-0341923
SIC Code 2836

Key Executives

Name Position
Tamara L. Lundgren J.D. Chairman, President and Chief Executive Officer
Stefano R. Gaggini CPA Chief Financial Officer and Senior Vice President
James Matthew Vaughn J.D. Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer
Steven G. Heiskell Senior Vice President and President of Products and Services
Brian Souza Senior Vice President, Chief Operations Management Officer and Chief of Ferrous Sales and Trading
Marc E. Hathhorn Chief Operating Officer and Executive Vice President
Erika K. Kelley Chief Accounting Officer and Vice President
Michael Bennett Vice President of Investor Relations
Robert Stone Vice President of Corporate Development
Erich D. Wilson Senior Vice President, Chief Human Resources Officer and Chief of Corporate Operations

Latest SEC Filings

Date Type Title
Jul 10, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 10, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 10, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 10, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 10, 2025 25-NSE Filing
Jul 10, 2025 8-K Current Report
Jul 7, 2025 8-K Current Report
Jul 1, 2025 10-Q Quarterly Report
Jul 1, 2025 8-K Current Report
Jun 20, 2025 8-K Current Report